With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Tyenne® is Fresenius ...
Patients treated with TYENNE ® (tocilizumab-aazg) are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive ...
Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare & Medicaid Services has issued ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific ...
Fresenius Kabi's tocilizumab biosimilar Tyenne ® is the first and only tocilizumab biosimilar to be launched in Canada and is now commercially available for both subcutaneous and intravenous ...
LAKE ZURICH, Ill., April 09, 2026--(BUSINESS WIRE)--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for ...
LAKE ZURICH, Ill., October 29, 2024--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results